Get the Stockscreener App
58.65
0.88%
-0.52
Pre-market:
58.01
-0.64
-1.09%
Biomarin Pharmaceutical Inc stock is traded at $58.65, with a volume of 1.35M.
It is down -0.88% in the last 24 hours and down -17.67% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
See More
Previous Close:
$59.17
Open:
$58.49
24h Volume:
1.35M
Relative Volume:
0.81
Market Cap:
$11.44B
Revenue:
$2.75B
Net Income/Loss:
$322.29M
P/E Ratio:
35.12
EPS:
1.67
Net Cash Flow:
$300.88M
1W Performance:
-1.71%
1M Performance:
-17.67%
6M Performance:
-16.55%
1Y Performance:
-33.83%
1-Day Range:
$58.29
$59.91
1-Week Range:
$58.00
$60.93
52-Week Range:
$52.93
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
58.65 | 11.44B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Oppenheimer maintains BioMarin stock Outperform with $98 target By Investing.com - Investing.com Nigeria
Oppenheimer maintains BioMarin stock Outperform with $98 target - Investing.com
Joshua Grass, John Kelly, and Lauren Daniel Join 5AM Ventures - GlobeNewswire Inc.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET - Longview News-Journal
Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal - insights.citeline.com
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction - Benzinga
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance
With BioMarin deal, Spruce Biosciences hits reset on rare-disease drugSan Francisco Business Times - The Business Journals
Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin - marketscreener.com
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength? - Yahoo Finance
Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day - TradingView
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On - Yahoo Finance
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 - Yahoo Finance
What Makes BioMarin (BMRN) a New Buy Stock - Yahoo Finance
BMRN vs. CSLLY: Which Stock Is the Better Value Option? - Yahoo Finance
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
BMRN stock touches 52-week low at $60.63 amid market shifts - Investing.com Canada
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study - MSN
BioMarin succeeds in trial for its metabolic disorder treatment - MSN
Edmond DE Rothschild Holding S.A. Boosts Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion (BMRN) - Seeking Alpha
Nomura Asset Management Co. Ltd. Sells 73,310 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint - Yahoo Finance
The Top 12 Companies Hiring in Biopharma Now - BioSpace
BioMarin (BMRN) Advances PALYNZIQ in Key Late-Stage Trial for PK - GuruFocus
BioMarin’s PALYNZIQ shows promise for adolescents with PKU - Investing.com India
BioMarin’s PALYNZIQ shows promise for adolescents with PKU By Investing.com - Investing.com South Africa
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients - Yahoo
BioMarin's Trial for Phenylketonuria Shows Palynziq Reduces Blood Phenylalanine in Adolescents - MarketScreener
Is BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now? - MSN
Is Royalty Pharma plc (RPRX) The Most Profitable Biotech Stock To Buy Right Now? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales - MSN
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria - PR Newswire
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
The Price Is Right For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - simplywall.st
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
US FDA approves Sanofi's bleeding disorder therapy - MarketScreener
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Yahoo Finance
Pharma Boom: BioMarin’s Surprising Surge - timothysykes.com
Is BioMarin Pharmaceutical Inc. (BMRN) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Holdings Lifted by Sector Gamma AS - MarketBeat
Insider Sell Alert: Erin Burkhart Sells Shares of Biomarin Pharm - GuruFocus
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):